ALX Oncology Highlights Evorpacept Data in Metastatic Breast Cancer at SABCS 2024
核心洞察
ALX Oncology presented initial Phase 1b/2 data on evorpacept combined with zanidatamab for heavily pretreated metastatic breast cancer (搜索) at SABCS 2024.
The virtual event on December 17 will feature an overview of the data by principal investigator Dr. Alberto J. Montero and ALX Oncology's CMO, Dr. Alan Sandler.
Evorpacept, a CD47 (搜索) blocker, is being investigated as a potential cornerstone therapy in immuno-oncology across various cancer indications.
ALX Oncology is set to host a virtual event on December 17 to discuss the first clinical data from its Phase 1b/2 trial of evorpacept in combination with zanidatamab for metastatic breast cancer (搜索). The data were initially presented at the San Antonio Breast Cancer (搜索) Symposium (SABCS) 2024.
The trial focuses on heavily pretreated patients with metastatic breast cancer (搜索), evaluating the efficacy and safety of evorpacept, a CD47 (搜索) blocker, in conjunction with zanidatamab. The virtual event will feature insights from Dr. Alberto J. Montero, the study's principal investigator, who will provide an overview of the data presented at SABCS 2024. Dr. Alan Sandler, ALX Oncology’s Chief Medical Officer, will also participate in a fireside chat.
Virtual Event Details
The virtual event is scheduled for Tuesday, December 17, at 8:00 AM EST. Jason Lettmann, Chief Executive Officer at ALX Oncology, will provide opening and closing remarks, highlighting progress and upcoming milestones for the company's evorpacept clinical program. The live webcast can be accessed through the Investors section of ALX Oncology's website. An archived webcast will be available following the event.
About Evorpacept
Evorpacept is ALX Oncology's lead therapeutic candidate, designed to boost the immune system to treat cancer. It is currently being evaluated in multiple ongoing clinical trials across a wide range of cancer indications, with the potential to serve as a cornerstone therapy in immuno-oncology.